Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT00858338 Completed - Gastric Cancer Clinical Trials

Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer

Start date: December 2002
Phase: Phase 2
Study type: Interventional

This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.

NCT ID: NCT00857246 Completed - Gastric Cancer Clinical Trials

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This study intends to evaluate the feasibility and treatment efficacy of adding an antibody blocking the epidermal growth factor (EGF) pathway to a neoadjuvant approach with proven efficacy developed at New York University.

NCT ID: NCT00854854 Enrolling by invitation - Clinical trials for Advanced Gastric Cancer

Efficacy Study of TKcell in Advanced Gastric Cancer

Start date: January 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine efficacy of NKCell combined FOLFOX-4 chemotherapy in gastric cancer

NCT ID: NCT00851305 Completed - Stomach Neoplasms Clinical Trials

Detection of Early Gastric Cancers Using Confocal Laser Endomicroscopy

CLE
Start date: August 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether endomicroscopy can improve the detection of Early Gastric Cancers (EGC).

NCT ID: NCT00848783 Terminated - Gastric Cancer Clinical Trials

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

Start date: May 2008
Phase: Phase 2
Study type: Interventional

This study is to determine whether intraperitoneal (IP) Floxuridine is effective in the patients with advanced stomach or gastro-esophageal junction cancers in the treatment consisting of pre- and post-surgery chemotherapies.

NCT ID: NCT00845884 Not yet recruiting - Clinical trials for Advanced Gastric Cancer

Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

In spite of multiple attempts to improve the efficacy of first-line chemotherapy in advanced gastric cancer, the progress that has been achieved so far is rather limited, and many investigators are exploring newer regimens.A combination of decetaxel (Taxotere) with Cisplatin and 5-fluorouracil (5FU) is considered one of the most effective regimens in this disease. However, it is associated with significant toxicity which avoided its general adaptation by the medical community. The current study is exploring a newer way to administer these three drugs, hopefully making the regimen more comfortable, less toxic and maybe even more effective. We will do this by changing the dose and timing of Taxotere and Cisplating, by replacing protracted infusion of 5FU with tablets of Capecitabine (Xeloda) and by adding the anti-angiogenic drug, Bevacizumab (Avastin), which had shown encouraging results in this disease.

NCT ID: NCT00845611 Completed - Gastric Cancer Clinical Trials

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent gastric cancer.

NCT ID: NCT00842491 Completed - Clinical trials for Advanced Gastric Cancer

Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether endostar (recombinant human endostatin)with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective and safe.

NCT ID: NCT00842244 Completed - Stomach Neoplasms Clinical Trials

Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

Start date: April 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.

NCT ID: NCT00836992 Completed - Colorectal Cancer Clinical Trials

Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer

Start date: January 2009
Phase: N/A
Study type: Observational

RATIONALE: Gathering information about patients' quality of life during radiation therapy for cancer may help doctors plan the best treatment. PURPOSE: This randomized clinical trial is studying quality of life in patients undergoing radiation therapy for primary lung cancer, head and neck cancer, or gastrointestinal cancer.